{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:41:34Z","timestamp":1791308494463,"version":"4.3.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ijcard.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T21:05:21Z","timestamp":1411160721000},"page":"400-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance"],"prefix":"10.1016","volume":"177","author":[{"given":"B.E.","family":"Smid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van der Tol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-5621","authenticated-orcid":false,"given":"F.","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.","family":"Lekanne Deprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Florquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Postema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tomberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"van den Bergh Weerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.09.001_bb0015","author":"Online Mendelian Inheritance of Man (OMIM)"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1-2","key":"10.1016\/j.ijcard.2014.09.001_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0035","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3733","article-title":"Alpha-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"issue":"12","key":"10.1016\/j.ijcard.2014.09.001_bb0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcard.2014.09.001_bb0055","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson\u2013Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson\u2013Fabry Disease Survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"10.1016\/j.ijcard.2014.09.001_bb0065","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"9813","key":"10.1016\/j.ijcard.2014.09.001_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijcard.2014.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.ijcard.2014.09.001_bb0085","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2011","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0095","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2012_167","article-title":"Questioning the pathogenic role of the GLA p.Ala143Thr \u2018mutation\u2019 in Fabry Disease: implications for screening studies and ERT","volume":"8","author":"Terryn","year":"2013","journal-title":"JIMD Rep"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ymgme.2012.10.018","article-title":"No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the alpha-galactosidase A gene","volume":"107","author":"Kobayashi","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"Tol van der","year":"2014","journal-title":"J Med Genet"},{"issue":"34","key":"10.1016\/j.ijcard.2014.09.001_bb0115","first-page":"802","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"11","author":"Yousef","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijcard.2014.09.001_bb0130","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry Disease","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: Lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0145","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study: screening genetic conditions in Portuguese young stroke patients","volume":"41","author":"Baptista","year":"2010","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0150","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0160","series-title":"An experimental application of the Delphi method to the use of experts","author":"Dalkey","year":"1962"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0175","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.HYP.23.5.600","article-title":"Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults","volume":"23","author":"de Simone","year":"1994","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ijcard.2014.09.001_bb0180","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.hrthm.2008.03.037","article-title":"Accurate electrocardiographic assessment of the QT interval: teach the tangent","volume":"5","author":"Postema","year":"2008","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2005.08.023","article-title":"Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy","volume":"111","author":"Hoigne","year":"2006","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(83)90084-X","article-title":"Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients","volume":"52","author":"Roberts","year":"1983","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2011.09.052","article-title":"Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease","volume":"109","author":"Namdar","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0200","first-page":"1","article-title":"A Technique for the Measurement of Attitudes","volume":"140","author":"Likert","year":"1932","journal-title":"Arch Psychol"},{"issue":"8","key":"10.1016\/j.ijcard.2014.09.001_bb0205","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2522\/ptj.20100262","article-title":"Content validity of the extended ICF Core Set for stroke: an international Delphi survey of physical therapists","volume":"91","author":"Glassel","year":"2011","journal-title":"Phys Ther"},{"issue":"7080","key":"10.1016\/j.ijcard.2014.09.001_bb0210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","article-title":"Cronbach's alpha","volume":"314","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"issue":"447","key":"10.1016\/j.ijcard.2014.09.001_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"21","key":"10.1016\/j.ijcard.2014.09.001_bb0225","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2008.02.046","article-title":"The binary endocardial appearance is a poor discriminator of Anderson\u2013Fabry disease from familial hypertrophic cardiomyopathy","volume":"51","author":"Kounas","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ijcard.2014.09.001_bb0230","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance (\u2018binary sign\u2019) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur J Echocardiogr"},{"issue":"8","key":"10.1016\/j.ijcard.2014.09.001_bb0235","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","article-title":"Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization","volume":"47","author":"Pieroni","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ijcard.2014.09.001_bb0240","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0245","doi-asserted-by":"crossref","first-page":"W97","DOI":"10.2214\/AJR.08.1201","article-title":"Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy","volume":"192","author":"De Cobelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.ijcard.2014.09.001_bb0250","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0255","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0260","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0270","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.icu.0000143688.45232.15","article-title":"Drug-induced corneal complications","volume":"15","author":"Hollander","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"10.1016\/j.ijcard.2014.09.001_bb0275","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","article-title":"Fabry disease: an underrecognized cause of proteinuria","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0280","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3928\/00904481-20090401-01","article-title":"A 14-year-old boy with pain in hands and feet","volume":"38","author":"Charrow","year":"2009","journal-title":"Pediatr Ann"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0285","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1373\/clinchem.2006.079012","article-title":"HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma","volume":"53","author":"Groener","year":"2007","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0290","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"443","key":"10.1016\/j.ijcard.2014.09.001_bb0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","article-title":"Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases","volume":"92","author":"Elleder","year":"2003","journal-title":"Acta Paediatr Suppl"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0300","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0305","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"10","key":"10.1016\/j.ijcard.2014.09.001_bb0310","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0046-8177(90)90258-7","article-title":"Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease","volume":"21","author":"Ogawa","year":"1990","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0315","first-page":"261","article-title":"Lipid storage disease: Part III. Ultrastructural evaluation of cultured fibroblasts in sphingolipidoses","volume":"37","author":"Takahashi","year":"1987","journal-title":"Acta Pathol Jpn"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0320","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1054-8807(02)00118-7","article-title":"Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease","volume":"11","author":"Roos","year":"2002","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0325","first-page":"448","article-title":"Renal involvement in Neimann\u2013Pick disease","volume":"2","author":"Grafft","year":"2009","journal-title":"Nephrol Dial Transplant Plus"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0330","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ymgme.2006.11.006","article-title":"Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B","volume":"90","author":"Ryazantsev","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0335","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.carpath.2011.10.001","article-title":"2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology","volume":"21","author":"Leone","year":"2012","journal-title":"Cardiovasc Pathol"},{"issue":"19","key":"10.1016\/j.ijcard.2014.09.001_bb0340","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.humpath.2012.04.023","article-title":"Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy","volume":"44","author":"Frustaci","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0350","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0355","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0360","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000085709","article-title":"Fabry disease in patients with end-stage renal failure: the potential benefits of screening","volume":"101","author":"Bekri","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"11","key":"10.1016\/j.ijcard.2014.09.001_bb0365","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","article-title":"Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy","volume":"14","author":"van der Zwaag","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0370","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.107.726752","article-title":"Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations","volume":"117","author":"Wolf","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0380","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijcard.2011.03.023","article-title":"MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease","volume":"160","author":"Koeppe","year":"2012","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.ijcard.2014.09.001_bb0385","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ijcard.2014.09.001_bb0390","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.echo.2011.05.021","article-title":"Tei index in Fabry disease","volume":"24","author":"Niemann","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"issue":"23","key":"10.1016\/j.ijcard.2014.09.001_bb0395","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0400","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10545-012-9540-8","article-title":"Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease","volume":"36","author":"Niemann","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0405","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0410","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant alpha-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"107","author":"Mitobe","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.ijcard.2014.09.001_bb0415","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/heart.89.8.929","article-title":"Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?","volume":"89","author":"Ommen","year":"2003","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0420","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"17","key":"10.1016\/j.ijcard.2014.09.001_bb0425","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","article-title":"Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period","volume":"118","author":"Holzmann","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0430","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380030204","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0435","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0440","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0445","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883\u2013884","author":"Kruger","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"10.1016\/j.ijcard.2014.09.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0455","article-title":"Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance","author":"Smid","year":"2014","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0460","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"The identification and assessment of Anderson\u2013Fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0465","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/hrt.2010.211789","article-title":"Electrocardiographic changes in early recognition of Fabry disease","volume":"97","author":"Namdar","year":"2011","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0470","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.amjcard.2009.10.056","article-title":"PQ interval in patients with Fabry disease","volume":"105","author":"Namdar","year":"2010","journal-title":"Am J Cardiol"},{"issue":"1\u20132","key":"10.1016\/j.ijcard.2014.09.001_bb0475","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.1016\/j.ijcard.2014.09.001_bb0480","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson\u2013Fabry disease","volume":"13","author":"O'Mahony","year":"2011","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0485","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.hlc.2007.03.007","article-title":"Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study","volume":"16","author":"Sadick","year":"2007","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0490","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0495","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson\u2013Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0500","first-page":"622","article-title":"Electrophysiological mechanism of the short PR interval in Pompe disease","volume":"128","author":"Gillette","year":"1974","journal-title":"Am J Dis Child"},{"issue":"7","key":"10.1016\/j.ijcard.2014.09.001_bb0505","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy","volume":"13","author":"Forsha","year":"2011","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0510","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"issue":"439","key":"10.1016\/j.ijcard.2014.09.001_bb0515","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2002.tb03106.x","article-title":"Isolated cardiac manifestations in Fabry disease: the UK experience","volume":"91","author":"Sachdev","year":"2002","journal-title":"Acta Paediatr Suppl"},{"issue":"9","key":"10.1016\/j.ijcard.2014.09.001_bb0520","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0525","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8175.2005.03191.x","article-title":"Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male","volume":"22","author":"Magage","year":"2005","journal-title":"Echocardiography"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0535","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1651-2227.2010.02101.x","article-title":"Safety of agalsidase alfa in patients with Fabry disease under 7years","volume":"100","author":"Ramaswami","year":"2011","journal-title":"Acta Paediatr"},{"issue":"9","key":"10.1016\/j.ijcard.2014.09.001_bb0540","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ijcard.2014.09.001_bb0545","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0550","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0555","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.ijcard.2014.09.001_bb0560","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijcard.2014.09.001_bb0565","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0570","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"Lobo","year":"2008","journal-title":"Intern Med J"},{"issue":"11","key":"10.1016\/j.ijcard.2014.09.001_bb0575","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"10.1016\/j.ijcard.2014.09.001_bb0580","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1540-8175.2012.01704.x","article-title":"Systolic myocardial mechanics in patients with Anderson\u2013Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy","volume":"29","author":"Gruner","year":"2012","journal-title":"Echocardiography"},{"issue":"15","key":"10.1016\/j.ijcard.2014.09.001_bb0585","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0590","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy","volume":"132","author":"Toro","year":"2009","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0595","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy","volume":"132","author":"Toro","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0600","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jacc.2008.07.074","article-title":"Binary sign in Anderson\u2013Fabry cardiomyopathy","volume":"53","author":"Pieroni","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0605","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1475-097X.2008.00851.x","article-title":"Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance","volume":"29","author":"Koskenvuo","year":"2009","journal-title":"Clin Physiol Funct Imaging"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0610","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ejechocard\/jen129","article-title":"Anderson\u2013Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy","volume":"9","author":"Kovacevic-Preradovic","year":"2008","journal-title":"Eur J Echocardiogr"},{"issue":"6 Pt 1","key":"10.1016\/j.ijcard.2014.09.001_bb0615","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-8703(80)90060-5","article-title":"The M-mode echocardiogram in Fabry's disease","volume":"100","author":"Bass","year":"1980","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0620","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2010","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0625","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-9149(01)02238-X","article-title":"Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)","volume":"89","author":"Bella","year":"2002","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ijcard.2014.09.001_bb0630","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.02.007","article-title":"Dilation of the aortic root in mitochondrial disease patients","volume":"103","author":"Brunetti-Pierri","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ijcard.2014.09.001_bb0635","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00246-009-9537-8","article-title":"PTPN11 mutation associated with aortic dilation and hypertrophic cardiomyopathy in a pediatric patient with Noonan syndrome","volume":"31","author":"Jefferies","year":"2010","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"10.1016\/j.ijcard.2014.09.001_bb0640","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2214\/AJR.05.0442","article-title":"MRI characterization of myocardial tissue in patients with Fabry's disease","volume":"188","author":"Imbriaco","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijcard.2014.09.001_bb0645","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/heartjnl-2012-302346","article-title":"Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease","volume":"98","author":"Sado","year":"2012","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ijcard.2014.09.001_bb0650","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/10976640701693691","article-title":"Altered myocardial motion pattern in Fabry patients assessed with CMR-tagging","volume":"9","author":"Rutz","year":"2007","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314017033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314017033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:16:04Z","timestamp":1717341364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314017033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0167527314017033"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.001","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}